Latest Life Sciences News

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Microba Life Sciences has wrapped up a $5.41 million capital raise combining a $5 million institutional Placement and a $407,500 Share Purchase Plan, strengthening its balance sheet to accelerate growth in Australia and the UK.

ALS Limited reported record FY26 financial results driven by strong growth in Minerals and Industrial Materials, while advancing its digital transformation through the Lab of the Future initiative. Leadership changes and a strategic portfolio review underpin its disciplined capital allocation approach.

Vitrafy Life Sciences has partnered with the historic Hoxworth Blood Center to deploy its next-generation cryopreservation technology, aiming to address a critical gap in red blood cell preservation ahead of legacy technology discontinuation in 2027.

AnteoTech has secured independent validation for its Ultranode™ 95 silicon anode in commercial drone battery cells, launched a new battery additive, and strengthened its cash position with a A$10 million capital raise.

Microba Life Sciences has delivered robust FY26 growth in its core microbiome testing business, with revenues up 92% year-on-year and a new GI Navigator product set for launch in September 2026. The company also announced a $7 million annualised cost reduction program as it advances towards cashflow break-even.

Ryder Capital posted a robust 33.53% pre-tax NTA return for FY26, far outpacing market benchmarks, and announced a fully franked 12 cents per share dividend for FY27, underscoring confidence in its small-cap portfolio.

Lendlease has partnered with The Crown Estate to form the Impact Partnership Joint Venture, unlocking a £24 billion UK development pipeline including up to 30,000 new homes and nearly a million square metres of office and life sciences space.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.

Booster Innovation Fund reported a $1.593 million profit for the year ended March 2026, supported by increased net assets. However, valuation risks persist due to early-stage investments and recent capital raises at lower prices.

ALS Limited (ASX:ALQ) has delivered a landmark FY26 with underlying net profit after tax surging 25.8% to $381.2 million, beating 2027 targets a year early and raising its dividend by 10%. The company continues to invest heavily in automation, digital initiatives, and laboratory expansions while advancing its climate strategy amid a post-year-end cyber incident.

Lendlease is selling its 25.1% stake in the Keyton Retirement Living Trust to Aware Super for $525 million, part of a broader $3.4 billion capital recycling push aimed at debt reduction.